Disclosed is the use of a peptide having an ability to bind to an HLA-A*1101 molecule, and an ability to induce a cytotoxic T lymphocyte comprising the amino acid sequence Ser Ala Ser Glu Thr Ser Slu Lys Arg, wherein one to five amino acids may be substituted with other amino acids, in the manufacture of a medicament for the treatment or prevention of cancer in an HLA-A*1101-positive subject, provided said patient is not HLA-A*3101-positive.
